-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Ascendis Pharma, Raises Price Target to $315

Benzinga·11/13/2026 16:44:05
UBS analyst Joon Lee maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $269 to $315.